Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis

摘要: Lumiracoxib is a COX2 inhibitor that highly selective, more effective than placebo on pain in osteoarthritis (OA), with similar analgesic and anti-inflammatory effects as non-selective NSAIDs the selective celecoxib, has lower incidence of upper gastrointestinal (GI) side patients not taking aspirin, cardiovascular (CV) compared to naproxen or ibuprofen. In context earlier guidelines into account GI CV safety results TARGET study, lumiracoxib had secured European Medicines Agency (EMEA) approval indication symptomatic treatment OA well short-term management acute associated primary dysmenorrhea following orthopedic dental surgery. complex clinical efficiency COX inhibitors, its prescription use should be based risk profile patient. addition, there further need for long-term studies general post-marketing daily practice. Meanwhile, at time submission this manuscript, EMEA withdrawn throughout Europe because serious affecting liver.